Costanza Pellegrini1, Oliver Husser1, Won-Keun Kim2, Andreas Holzamer3, Thomas Walther4, Tobias Rheude1, Nicola Patrick Mayr5, Teresa Trenkwalder1, Michael Joner6, Jonathan Michel1, Fabian Chaustre1, Adnan Kastrati6, Heribert Schunkert6, Christof Burgdorf7, Michael Hilker3, Helge Möllmann8, Christian Hengstenberg9. 1. Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany. 2. Department of Cardiology, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany; Department of Cardiovascular Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany. 3. Klinik für Herz-, Thorax-, und herznahe Gefäßchirurgie, University of Regensburg Medical Center, Regensburg, Germany. 4. Department of Cardiovascular Surgery, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany. 5. Institut für Anästhesiologie, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany. 6. Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany; Deutsches Zentrum für Herz- und Kreislauf-Forschung (DZHK) e.V. (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. 7. Herz- und Gefäßzentrum Bad Bevensen, Klinik für Kardiologie, Bad Bevensen, Germany. 8. Department of Cardiology, Kerckhoff Heart and Lung Center, Bad Nauheim, Germany. 9. Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany; Deutsches Zentrum für Herz- und Kreislauf-Forschung (DZHK) e.V. (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany; Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. Electronic address: christian.hengstenberg@meduniwien.ac.at.
Abstract
INTRODUCTION AND OBJECTIVES: The incidence of permanent pacemaker implantation (PPI) and new conduction abnormalities (CA) with the ACURATE neo (Symetis S.A., Eclubens, Switzerland) has not been studied in detail. We aimed to analyze their predictors, evaluating patient- and device-related factors, including implantation depth and device-to-annulus ratio (DAR). METHODS: Two analyses of a multicenter population were performed: new PPI in pacemaker-naive patients (n = 283), and PPI/new-CA in patients without prior CA or pacemaker (n = 232). RESULTS: A new PPI was required in 9.9% of patients, who had a higher body mass index, higher rate of right bundle branch block and bradycardia. Neither implantation depth nor DAR differed in patients with PPI compared with those without. In the multivariable analysis neither DAR (OR, 1.010; 95%CI, 0.967-1.055; P = .7) nor implantation depth (OR, 0.972; 95%CI, 0.743-1.272; P = .8) predicted PPI. Only high body mass index, bradycardia and right bundle branch block persisted as independent predictors. PPI/new-onset CA occurred in 22.8% of patients and was associated with a higher logistic EuroSCORE. Neither implantation depth nor DAR differed in patients with PPI/new-CA vs those without (7.3 ± 1.9 vs 7.1 ± 1.5mm; P = .6 and 41.0 ± 7.9 vs 42.2 ± 10.1%; P = .4). The only predictor of PPI/new-CA was a higher logistic EuroSCORE (OR, 1.039; 95%CI, [1.008-1.071]; P = .013). CONCLUSIONS: New PPI and new-onset CA rates were low with the ACURATE neo. These were mainly influenced by patient characteristics and not by device-depending factors.
INTRODUCTION AND OBJECTIVES: The incidence of permanent pacemaker implantation (PPI) and new conduction abnormalities (CA) with the ACURATEneo (Symetis S.A., Eclubens, Switzerland) has not been studied in detail. We aimed to analyze their predictors, evaluating patient- and device-related factors, including implantation depth and device-to-annulus ratio (DAR). METHODS: Two analyses of a multicenter population were performed: new PPI in pacemaker-naive patients (n = 283), and PPI/new-CA in patients without prior CA or pacemaker (n = 232). RESULTS: A new PPI was required in 9.9% of patients, who had a higher body mass index, higher rate of right bundle branch block and bradycardia. Neither implantation depth nor DAR differed in patients with PPI compared with those without. In the multivariable analysis neither DAR (OR, 1.010; 95%CI, 0.967-1.055; P = .7) nor implantation depth (OR, 0.972; 95%CI, 0.743-1.272; P = .8) predicted PPI. Only high body mass index, bradycardia and right bundle branch block persisted as independent predictors. PPI/new-onset CA occurred in 22.8% of patients and was associated with a higher logistic EuroSCORE. Neither implantation depth nor DAR differed in patients with PPI/new-CA vs those without (7.3 ± 1.9 vs 7.1 ± 1.5mm; P = .6 and 41.0 ± 7.9 vs 42.2 ± 10.1%; P = .4). The only predictor of PPI/new-CA was a higher logistic EuroSCORE (OR, 1.039; 95%CI, [1.008-1.071]; P = .013). CONCLUSIONS: New PPI and new-onset CA rates were low with the ACURATEneo. These were mainly influenced by patient characteristics and not by device-depending factors.
Authors: Alberto Alperi; Guillem Muntané-Carol; Afonso B Freitas-Ferraz; Lucia Junquera; David Del Val; Laurent Faroux; François Philippon; Josep Rodés-Cabau Journal: Ann Cardiothorac Surg Date: 2020-11
Authors: Costanza Pellegrini; Tobias Rheude; Teresa Trenkwalder; N Patrick Mayr; Michael Joner; Adnan Kastrati; Heribert Schunkert; Oliver Husser; Christian Hengstenberg Journal: Clin Res Cardiol Date: 2019-05-02 Impact factor: 5.460
Authors: Costanza Pellegrini; Tobias Rheude; Teresa Trenkwalder; N Patrick Mayr; Jonathan Michel; Adnan Kastrati; Heribert Schunkert; Albert M Kasel; Michael Joner; Christian Hengstenberg; Oliver Husser Journal: Catheter Cardiovasc Interv Date: 2019-02-24 Impact factor: 2.692
Authors: Costanza Pellegrini; Tobias Rheude; Jonathan Michel; Hector A Alvarez-Covarrubias; Sarah Wünsch; N Patrick Mayr; Erion Xhepa; Adnan Kastrati; Heribert Schunkert; Michael Joner; Markus Kasel Journal: J Thorac Dis Date: 2020-11 Impact factor: 2.895